Northrop Grumman's Last Three Years: The Same B-21 Setback, Twice

The story

Fall 2023: confident, and no hint of trouble yet

In October 2023, on the Q3 earnings call, CEO Kathy Warden announced a record backlog of $84B and a 1.5x book-to-bill, guided 2024 revenue and operating-income growth of 4–5%, and projected free cash flow growing more than 20% annually in the years ahead. The B-21 stealth bomber, she said, remained on track for a "first flight this year." There was no mention yet of any program-cost trouble.

January 2024: two setbacks land in the same call

Three months later, on the January 25, 2024 Q4 call, Warden used the word "disappointed" and disclosed a $1.56 billion loss provision covering all five low-rate-initial-production lots of the B-21 bomber. In the same call, the Army's next-generation Sentinel intercontinental ballistic missile program was disclosed as having entered a Nunn-McCurdy cost-overrun review — a term that appeared zero times in the FY2022 10-K and began appearing regularly starting with the FY2023 filing.

The response: acknowledge the loss, then double down on the forecast

On that same call — the one disclosing the loss — Warden stated the company's multi-year free-cash-flow outlook was unchanged, and for the first time gave a specific new target: $3.3 billion of free cash flow by 2026. The following four quarters of 2024 all held or raised guidance, and by October 2024 the company posted its best margin in two years (11.5%). A CFO transition — Dave Keffer to Ken Crews, effective October 2024 — happened in the same window without disrupting the trend.

2025: the same pattern repeats, almost exactly

Then, in April 2025, the identical sequence played out again: a second B-21 loss provision of $477 million, described again as "disappointed with this financial impact," alongside a 7% year-over-year revenue decline tied to order-timing delays. Six months later, on the October 2025 Q3 call, the company cut its full-year revenue guidance — the only guidance cut in the three-year period reviewed — citing program-schedule delays. Even so, management highlighted the same call's margin (12.3%) and free-cash-flow (+72% year over year) improvements in the same breath.

Where it stands now: from repair to acceleration

By the January 2026 Q4 call, Northrop reported that 2025 revenue and EPS both exceeded the top end of guidance, and that free cash flow of $3.3 billion had hit the target originally set for 2026 — a full year early. The same call saw a second CFO transition, with 20-year veteran Ken Crews handing off to external hire John Green. By July 2026 (Q2), backlog hit a record $105 billion, book-to-bill reached 1.84x, and guidance was raised again.

Guidance vs. actual results

Source: quarterly earnings-call transcripts; 10-K FY2023 and FY2025 for actual results.

Four of five completed guidance cycles were met or beaten, and the single cut (Q3 2025) still ended up beaten by year-end — making it, in hindsight, a conservative adjustment rather than a real miss. The B-21 program has now generated two separate loss provisions on the same underlying issue, which argues against declaring the risk fully closed even as the company's overall forecasting record stays strong.

Timeline

• Oct. 26, 2023Q3 call: record $84B backlog, 1.5x book-to-bill, optimistic 2024 outlook; no B-21 trouble disclosed yet.
• Jan. 25, 2024Q4 call: $1.56B B-21 loss provision across all five LRIP lots; Sentinel enters Nunn-McCurdy review. New "2026 FCF $3.3B" target set the same call.
• Oct. 2024CFO transition: Dave Keffer to Ken Crews.
• Oct. 24, 2024Q3 call: best operating margin in two years (11.5%); record backlog of $85B.
• Apr. 2025Q1 call: second B-21 loss provision ($477M); revenue down 7% year over year on order timing.
• Oct. 1–Nov. 12, 202543-day federal government shutdown; company later confirms "no material impact" on results.
• Oct. 2025Q3 call: full-year revenue guidance cut — the only cut in the period — on schedule delays.
• Jan. 7, 2026Second CFO transition: Ken Crews to external hire John Green.
• Jan. 27, 2026Q4 call: 2025 revenue and EPS both exceed guidance top end; FCF of $3.3B hits the 2026 target a year early.
• Jul. 21, 2026Q2 call: record $105B backlog, 1.84x book-to-bill, guidance raised again.

Our read

The three-year pattern here is consistent enough to call a playbook: shock, an honest admission, an immediate reaffirmation of the long-term forecast, and a beat within a few quarters. Taking a second write-down on the same B-21 program is a legitimate concern — it's hard to call the risk "resolved" after it recurred once already — but both times, the company held its multi-year guidance rather than retreating from it, and both times it delivered. One detail stands out on its own: a new risk-factor phrase quietly added to the FY2025 10-K, warning that an executive order could limit stock buybacks and dividends for underperforming defense contractors, has never once come up on an earnings call. It's a risk that lives only in the filing, not in the narrative management tells investors — worth watching precisely because no one is talking about it yet.

What we still don't know

• The final pricing for B-21 units 21–40 (the "not-to-exceed" range) is still unresolved as of the Q2 FY2026 call, leaving open the possibility of a third loss provision.
• Whether the new executive-order risk around buyback and dividend restrictions for underperforming contractors will ever be invoked — it's disclosed in the 10-K but has never been raised by an analyst or by management on any call reviewed.
• Second-half 2026 results will show whether the "guide conservatively, then beat" pattern continues after the Q2 FY2026 guidance raise.